The Exchange has sought clarification from Anthem Biosciences Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Anthem Biosciences to clarify why segment-wise details were not submitted along with its financial results for the quarter ended 30-June-2025. This is filed under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements (LODR) Rules, 2015, which governs how listed companies report quarterly results. The company's response is still awaited and has not been shared in this filing. The matter appears procedural rather than punitive at this stage.
This is a routine compliance clarification request and typically does not affect share price on its own. Shareholders should watch for the company's response to see if segment reporting reveals anything unusual about revenue or business mix.